⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21963992 | 1.00 | — | — | |
| SCHEMBL2031064 | 1.00 | — | — | |
| SCHEMBL2035483 | 0.84 | — | — | |
| SCHEMBL19692710 | 0.84 | — | — | |
| SCHEMBL14638692 | 0.79 | — | — | |
| SCHEMBL16985228 | 0.78 | — | — | |
| SCHEMBL23535429 | 0.77 | — | — | |
| SCHEMBL962003 | 0.77 | — | — | |
| SCHEMBL6189306 | 0.77 | — | — | |
| SCHEMBL2366618 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111909173-B | Benzoxazepine oxazolidinone compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-112047960-B | Benzoxazepine oxazolidinone compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-112062778-B | Benzoxazepine oxazolidinone compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11760753-B2 | Benzoxazepin oxazolidinone compounds and methods of use | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| EP-4212536-A1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2023-07-19 | — | — | EP | disclosed |
| CN-116265453-A | Compounds as AR inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2023-06-20 | — | — | CN | disclosed |
| EP-3567045-B1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2022-01-12 | — | — | EP | disclosed |
| US-20210246129-A1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2021-08-12 | — | — | US | disclosed |
| EP-3778607-A1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2021-02-17 | — | — | EP | disclosed |
| CN-112062778-A | Benzoxazepine compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2020-12-11 | — | — | CN | disclosed |
| EP-3317283-B1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2019-04-03 | — | — | EP | disclosed |
| US-20180127404-A1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| WO-2017140758-A1 | DERIVATIVES OF 2-AMINO-4-(2-OXAZOLIDINON-3-YL)-PYRIMIDINE FUSED WITH A FIVE-MEMBERED HETEROAROMATIC RING IN 5,6-POSITION WHICH ARE USEFUL FOR THE TREATMENT OF VARIOUS CANCERS | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2017-08-24 | — | — | WO | disclosed |
| US-20170210733-A1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| US-9650393-B2 | Benzoxazepin oxazolidinone compounds and methods of use | GENENTECH, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9643980-B2 | Benzoxazepin oxazolidinone compounds and methods of use | GENENTECH, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20170015678-A1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170002022-A1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| WO-2017001645-A1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-01-05 | — | — | WO | disclosed |
| WO-2017001658-A1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-01-05 | — | — | WO | disclosed |